Latest Content

AI predicted mechanism of action for investigational, narrow spectrum antibiotic against pathogens in Crohn's disease and IBD-related conditions.

David Perlin, PhD, chief scientific officer and executive vice president, the Center for Discovery and Innovation (CDI), talks about his team’s work around developing a diagnostic for Candida auris, and what they are working on in terms of developing antifungals.

The company is advancing R327G, a novel synthetic anti-infective for diabetic foot infections, through a phase 3 clinical trial in Indonesia, marking a major step toward the first new anti-infective class approval in over 40 years.

The Center for Discovery and Innovation’s chief scientific officer David Perlin, PhD, discusses the factors for the growing number of cases and the difficulties in developing such treatments.

Through the bipartisan Cure Hepatitis C Act of 2025, legislation seeks to provide nationwide hepatitis C treatment and strengthen public health infrastructure by expanding testing, treatment, and prevention through a subscription-based model.

The center’s chief scientific officer David Perlin, PhD, provides some insights on the evolution of its antiviral program from its foundation in treating COVID-19 to addressing all pan-coronaviruses.

Your liver silently powers and protects your body every day, but untreated hepatitis infections, excessive alcohol, and poor diet can destroy its vital cells, leading to fatigue, cirrhosis, and liver cancer if not prevented through awareness and care.

The US Department of Agriculture’s Food Safety and Inspection Service (FSIS) provides information on the 2 companies recalls and the products.

William Schaffner, MD, provides more context to the committee’s vaccines recommendations.

This week, there are C diff and hepatitis roundup reports, how COVID-19 has disrupted traditional respiratory virus patterns with summer surges now preceding the typical winter influenza season, a review of a trial comparing dalbavancin with standard intravenous therapy for Staphylococcus aureus, and more.

University of Oregon researchers found that adding a common chemical, chlorate, to standard antibiotics made them up to 10,000 times more effective in lab tests against hard-to-treat bacteria, offering a potential breakthrough for chronic wound care.

Infections caused by NDM-producing carbapenem-resistant Enterobacterales have risen more than 4-fold since 2019, raising alarms about limited treatment options, delayed detection, and heightened risks of transmission and mortality in health care settings. TAXIS Pharmaceuticals Chief Scientific Officer Ajit Parhi, PhD, offers some insights on NDM-CRE, antimicrobial resistance, and an overview of his company’s pipeline.

Recce Pharmaceuticals has begun its study for this indication in Indonesia with its investigational product, RECCE 327 topical gel (R327G).